Copyright
©The Author(s) 2021.
World J Gastroenterol. Apr 21, 2021; 27(15): 1595-1615
Published online Apr 21, 2021. doi: 10.3748/wjg.v27.i15.1595
Published online Apr 21, 2021. doi: 10.3748/wjg.v27.i15.1595
Figure 3 Construction of a human colon cancer SW480 cell model stably overexpressing Abelson interactor 1 splice isoform-L.
A: SW480 clone #3 overexpressing Abelson interactor 1 splice isoform-L (ABI1-SiL); B: SW480 clone #6 overexpressing ABI1-SiL; C: The ratio of ABI1-SiL to all Abelson interactor 1 (ABI1) isoforms was determined by quantitative polymerase chain reaction using ABI1 universal 1 and ABI1 universal 2 primers; D: Western blot demonstrating efficacy of ABI1-SiL overexpression. Lysates from 1 × 106 cells were separated by sodium dodecyl sulfate-polyacrylamide gel electrophoresis and transferred to a nitrocellulose membrane. The membrane was probed with the indicated antibodies. ABI1-SiL: Abelson interactor 1 splice isoform-L; ABI1: Abelson interactor 1; GFP: Green fluorescence protein; GAPDH: Glyceraldehyde-3-phosphate dehydrogenase.
- Citation: Li K, Peng YF, Guo JZ, Li M, Zhang Y, Chen JY, Lin TR, Yu X, Yu WD. Abelson interactor 1 splice isoform-L plays an anti-oncogenic role in colorectal carcinoma through interactions with WAVE2 and full-length Abelson interactor 1. World J Gastroenterol 2021; 27(15): 1595-1615
- URL: https://www.wjgnet.com/1007-9327/full/v27/i15/1595.htm
- DOI: https://dx.doi.org/10.3748/wjg.v27.i15.1595